Improving Immunotherapy by Modulating PD-1hiFoxp3-CD4+ T Cells in Melanoma

Why This Research Matters
Immunotherapy has revolutionized the treatment of melanoma – a deadly form of skin cancer, by enhancing the capacity of the body’s own immune system to find and destroy cancer cells. While this has saved many lives, many patients still do not respond to these treatments or eventually see their cancer return. This project contributes to understanding why this happens and how to overcome these challenges. The Discovery: Our team has identified a new “double-agent” in the immune system: a specific group of cells expressing high levels of the immune checkpoint PD-1, called 4PD1hi T cells. Although these cells lack expression of canonical markers defining known suppressive lymphocytes, they act as suppressors by shutting shut down the immune “soldier” cells that are trying to kill the tumor. We found that as melanoma grows, suppressive 4PD1hi cells accumulate and act as a shield for the cancer. The Innovation: The most exciting part of our research is that these cells are not permanently “suppressive”.

What We Are Studying
Our preliminary data shows a “phenotypic switch” of these cells in conditions associated with response to therapy. This suggests that if we can change these cells from a suppressive state to a “fighter” state (called Th1), the immune system can control the tumor better. We have identified a specific axis (the CXCL13:CXCR5 pathway) that seems to keep these cells in their “immunosuppressive” state. Our Plan: In this proposal, we will pursue two main goals: Find the Source: We will track where the suppressive nature of these cells is instructed—whether they are instructed to become suppressive in the lymph nodes or right inside the tumor. This helps us understand the best time and place to intervene. Flip the Switch: We will test new ways to block the signals that make these cells suppressive.

How the Study Works
By using specialized tools like CRISPR gene editing and new drugs targeting the CXCR5:CXCL13 axis, we aim to stop these cells from protecting the tumor and instead turn them into helpers that support the cancer-killing “soldiers”. Significance & Impact: This research is significant because it identifies a new target to make immunotherapy effective in more patients. By understanding how these suppressive 4PD1hi cells develop and work, we can identify new therapies tailored to target these cells in their suppressive state for potentiating current immunotherapies and overcoming resistance.

Expected Impact
Ultimately, this work aims to inform a new generation of treatments that neutralize a novel cancer’s immune defense mechanism. Because these same suppressive 4PD1hi cells are found in other types of cancer, our findings in melanoma could eventually lead to better cure rates for additional solid tumors that are currently difficult to treat.